Cholinergic immunomodulation in inflammatory bowel diseases

Brain, Behavior, & Immunity - Health

卷:19

Ana H. Paz¹  Michele A. Serafini²  Natalia S. Nunes³ 

[1] Cells, Tissue and Genes Laboratory, Experimental Research Center, Hospital de Clinicas de Porto Alegre, 90035903, Porto Alegre, Brazil;

[2] Biological Sciences, Physiology Graduate Program, Federal University of Rio Grande do Sul, 90050170, Porto Alegre, Brazil;

[3] Morphological Sciences Department, Basic Health Sciences Institute, Federal University of Rio Grande do Sul, 90050170, Porto Alegre, Brazil;

关键词: Cholinergic signaling;    Inflammatory bowel diseases;    Macrophage;    T cell;    Immunomodulation;    Acetylcholine;   

DOI  :  

来源: DOAJ

【 摘 要 】

Inflammatory bowel diseases (IBD) are chronic intestinal disorders characterized by dysregulated immune responses to resident microbiota in genetically susceptible hosts. The activation of the cholinergic system has been proposed for the treatment of IBD patients according to its potential anti-inflammatory effect in vivo. The α-7-nicotinic-acetylcholine receptor (α7nAChR) is involved in the inhibition of inflammatory processes, modulating the production of cytokines, suppressing dendritic cells and macrophage activity, leading to the suppression of T cells. In this review, we address the most recent studies and clinical trials concerning cholinergic signaling and its therapeutic potential for inflammatory bowel diseases.

【 授权许可】

Unknown